Literature DB >> 10608025

Optimizing the Treatment of Unstable Angina.

.   

Abstract

Unstable angina and non--Q-wave myocardial infarction (MI) are at the center of the spectrum of myocardial ischemia, which ranges from stable angina to acute Q-wave MI. In addition to clinical evaluation, cardiac specific markers such as troponin T or I can assist in early diagnosis, triage, and risk stratification. Antithrombotic therapy with aspirin and heparin have been shown to improve the outcome of patients with acute ischemic syndromes. Thrombolytic therapy does not appear to be beneficial in these syndromes. Antiischemic therapy remains an important component of the overall therapy. A strategy of early coronary angiography and revascularization leads to a similar long-term outcome as compared with a more conservative strategy of revascularization for recurrent ischemia, but the early invasive strategy is more expeditious as a large number of conservatively treated patients have recurrent ischemia. At present, many new antithrombotic agents are under active investigation, with the hope that they will lead to further improvement in the clinical outcome of patients with acute ischemic syndromes.

Entities:  

Year:  1995        PMID: 10608025     DOI: 10.1007/bf01062711

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  76 in total

1.  Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB.

Authors:  P R Puleo; P A Guadagno; R Roberts; M V Scheel; A J Marian; D Churchill; M B Perryman
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

2.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

3.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

4.  Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.

Authors:  R M Lidón; P Théroux; M Juneau; B Adelman; J Maraganore
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

5.  Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.

Authors:  P Théroux; D Waters; S Qiu; J McCans; P de Guise; M Juneau
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

6.  Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.

Authors: 
Journal:  Circulation       Date:  1993-01       Impact factor: 29.690

7.  [Intravenous thrombolysis in myocardial infarction. Influence of the quality of the anticoagulation on the early recurrence rate of angina or infarction].

Authors:  J F Camilleri; J L Bonnet; J L Bouvier; G Levy; P Djiane; M Bory; A Serradimigni
Journal:  Arch Mal Coeur Vaiss       Date:  1988-09

8.  Coronary angioscopy in patients with unstable angina pectoris.

Authors:  C T Sherman; F Litvack; W Grundfest; M Lee; A Hickey; A Chaux; R Kass; C Blanche; J Matloff; L Morgenstern
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

9.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321

10.  Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients.

Authors:  J Ravkilde; H Nissen; M Hørder; K Thygesen
Journal:  J Am Coll Cardiol       Date:  1995-03-01       Impact factor: 24.094

View more
  3 in total

Review 1.  Advances in the medical management of acute coronary syndromes.

Authors:  C P Cannon
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Low molecular weight heparin in acute coronary syndromes.

Authors:  C P Cannon
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 2.931

Review 3.  Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.

Authors:  Marc Cohen
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.